Fig. 4.
Decitabine reverses GATA3 silencing in PER-117 cells, an in vitro model for GATA3low ETP-ALL. a Treatment with decitabine (5 μM) increased GATA3 mRNA expression (n = 4, p < 0.001 indicated by the asterisk, all values are mean ± s.d.) and decreased GATA3 DNA methylation after 48 h (n = 4, p < 0.05 indicated by the asterisk, all values are mean ± s.d.) as detected by pyrosequencing. Note the two segments of the right y-axis for improved visualization. b Treatment with decitabine impaired proliferation as detected by WST assay with an IC50 of 4 μM and induced apoptosis as detected by flow cytometry of incorporation of 7-AAD and Annexin V binding after 48 h (n ≥ 5, p < 0.05 indicated by the asterisk, all values are mean ± s.d). c Principal component analysis of global gene expression profiles of PER-117 cells before and after treatment with decitabine (5 μM). d Venn diagram indicating the number of differentially expressed probe sets in PER-117 cells after 24 and 48 h and at both time points compared with no treatment